Global Meningococcal Vaccines Market is Predicted to Reach US$ 7,732.3 Million by the End of 2027, with a Value of US$ 3,341.9 Million

Meningococcal Vaccines

Meningococcal vaccination protects against diseases caused by Neisseria meningitides, often known as meningococcus, a Gram-negative bacterium that can cause meningitis and other kinds of meningococcal disease such as meningococcemia.

Drivers of the Global Meningococcal Vaccine Market

Over the projected period, a large number of people traveling to Sub-Saharan Africa is expected to drive the global Meningococcal Vaccines Market. In 2017, for example, 37.4 million tourists visited Sub-Saharan Africa, according to the World Economic Forum's 2018 report. Furthermore, the industry is likely to benefit from the recommendations of several regulatory authorities for a meningococcal vaccine. Meningococcal vaccines, for example, are recommended by the Centers for Disease Control and Prevention for preteens, teens, and certain other persons.

Restraints in the Global Meningococcal Vaccine Market

Both regionally and across time, significant changes in meningococcal illness incidence and epidemiology have been reported. As a result, comprehensive coverage addressing as many serogroups as possible is required. Because the risk associated with traveling is unexpected, providing evidence-based vaccine recommendations is more difficult. Such a scenario is likely to stifle market expansion. Furthermore, in several countries, Meningococcal Vaccines Market is optional, which is projected to impede the market growth.

Meningococcal Vaccines Market: Opportunities

The development of vaccines that do not require extremely restricted temperature ranges for storage is projected to provide attractive growth prospects for market players. Only one meningococcal vaccination, MenAfriVac, has been authorized for use outside of the cold chain yet. Meningococcal Vaccines Market Growth is also likely to be aided by the development of vaccines through collaborations and public-private partnerships. The PATH-WHO Meningitis Vaccine Project, an Indian vaccine maker Serum Institute of India Ltd., and public health experts in India and numerous African countries collaborated to develop the novel MenAfriVac meningococcal vaccine. In the African meningitis belt, the development was intended at delivering an effective, long-term, and economical solution to outbreaks caused by meningococcal illness.